Topic: Jeffrey Glenn
1/20/2010 Print E-mail A new class of compounds is able to inhibit replication of the hepatitis C virus (HCV) in laboratory tests, say U.S. scientists.. Chronic hepatitis C infection is the No. 1 cause of liver cancer and liver transplantation in the ...
US scientists have discovered a way to block replication of the hepatitis C virus, potentially leading to better treatment for the top cause of liver cancer in the United States, a study said Wednesday.In vitro experiments identified a protein that is essential ...
WASHINGTON (Reuters) - U.S. scientists have identified a new class of drugs that appear to block the hepatitis C virus from replicating in laboratory experiments, researchers said on Wednesday.The team discovered activity within a key protein of the hepatitis C virus (HCV) ...